New Diagnostic Method of Lymph Nodes metastases and Surgical Margins Using 5-Aminolevulinic Acid in Urothelial Carcinoma and Prostate Cancer.

New Diagnostic Method of Lymph Nodes metastases and Surgical Margins Using 5-Aminolevulinic Acid in Urothelial Carcinoma and Prostate Cancer. - Diagnosis of lymph nodes metastases of urological malignancy using 5-ALA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021068

Enrollment

250

Registered

2016-06-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial cancer, Prostate cancer

Interventions

Single oral dose of 5-ALA before surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Prostate or urothelial cancer who undergo prostatectomy, cystectomy or nephroureterectomy PS 0-1 given written informed consent

Exclusion criteria

Exclusion criteria: Porphyria Hypersensitivity of 5-ALA pregnant or possibly pregnant women severe cardiac, pulmonary, renal, hepatic, or hematopoietic impairment or uncontrolled diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactYoshio Naya

Kyoto Prefectural University of Medicine Department of Urology

ynaya@koto.kpu-m.ac.jp075-251-5595

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026